Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

Biotechnology firm Biocon Ltd on Monday (February 24) said its unit Biocon Biologics announced the US market availability of ...

YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

Biocon Biologics has announced that Yesintek (ustekinumab-kfce) is now available to patients in the United States, and is one of the first Stelara (ustekinumab) biosimilar market entrants in the ...

Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...

Biocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune ...

MedImpact Healthcare Systems, the nation’s largest independent provider of health solutions, technology, and pharmacy benefit ...

Biocon Biologics has introduced a biosimilar drug, YESINTEK, in the U.S. for treating autoimmune diseases like Crohn's disease, ulcerative colitis, and psoriasis. The launch represents a commitment to ...

Yesintek is supplied as a 45mg/0.5mL and 90mg/mL prefilled syringe, as well as a 45mg/0.5mL single-dose vial for SC injection. Additionally, a 130mg/26mL single-dose vial is available for IV infusion.

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.